WO2001082950A1 - Preparations d'insuline pouvant etre absorbees par voie pernasale - Google Patents
Preparations d'insuline pouvant etre absorbees par voie pernasale Download PDFInfo
- Publication number
- WO2001082950A1 WO2001082950A1 PCT/JP2001/003642 JP0103642W WO0182950A1 WO 2001082950 A1 WO2001082950 A1 WO 2001082950A1 JP 0103642 W JP0103642 W JP 0103642W WO 0182950 A1 WO0182950 A1 WO 0182950A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- calcium carbonate
- composition
- porous spherical
- particle size
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a preparation for intranasal absorption of insulin, and more particularly to a preparation using a specific form of calcium carbonate granules as a carrier, and a method for treating diabetes.
- Insulin is currently used as a therapeutic agent for diabetes in injectable preparations in clinical practice, and relatively simple subcutaneous preparations are mainly used for self-injection.
- relatively simple subcutaneous preparations are mainly used for self-injection.
- patients due to its nature as an injectable preparation, patients must self-inject 1 to 4 times before meals for a lifetime, and onerousness is one of the problems in treating diabetes. I have.
- intranasal administration is generally known as an administration route for transferring a drug into the blood in a short period of time, but there are no intranasal or intranasal preparations of insulin that have been practically used yet.
- nasal absorption preparations that have been tried are generally poor in absorption and unstable, and those that use certain absorption enhancers may not be irritating to the nasal mucosa. Therefore, it did not reach practical use.
- Japanese Patent Application Laid-Open No. 8-27031 discloses that as a composition for nasal absorption of various drugs including physiologically active peptides such as insulin and calcitonin, the drug is used as a carrier for a polyvalent metal compound. It discloses a composition that is uniformly dispersed and adhered. According to this disclosure, for example, by using hydroxyapatite, calcium carbonate, calcium lactate, magnesium stearate, or the like having an average particle size of 30 to 60 ⁇ am as a carrier, the drug is transferred into the body (or into the blood). It is suggested that good results are obtained. In this publication, an insulin preparation is specifically described, and an in vivo test is conducted. The nasal absorption composition containing hydroxyapatite having a particle diameter of 40 to 45 m as a carrier is described. There are things. The compositions have been demonstrated to produce a similar pattern of blood glucose (blood sugar) reduction as subcutaneous formulations.
- composition for nasal absorption described in JP-A-8-27031 is one of There is still a need for nasal compositions that achieve their stated purpose and are extremely useful, but which are further improved (eg, have increased bioavailability). There will be.
- an object of the present invention is to provide a preparation for intranasal absorption of insulin, which further enhances the bioavailability of insulin in the preparation.
- the present inventors have studied the combination of insulin and various carriers and the transfer of the drug into the blood when administered intranasally to achieve the above object. It has been found that the use of calcium can significantly increase the concentration of insulin transferred into the blood and can significantly lower the blood glucose level.
- the present invention is based on such findings.
- a preparation for nasal absorption of insulin comprising a composition comprising insulin and a porous spherical carbonated calcium carbonate as a carrier thereof, and a composition comprising insulin and calcium carbonate as a carrier thereof
- a preparation for nasal absorption of insulin containing the substance comprising a composition comprising insulin and a porous spherical carbonated calcium carbonate as a carrier thereof, and a composition comprising insulin and calcium carbonate as a carrier thereof
- a composition in which the carbonic acid ruthenium is composed of cubic or trigonal crystals (more specifically, derived from a pharmacopoeial product), and has a particle size in the range of 20 to 32 im.
- a composition comprising insulin and porous spherical calcium carbonate as a carrier thereof is administered to a diabetic patient in need of administering insulin so that an effective amount of insulin is administered. Also provided is a method of treating diabetes comprising nasal administration.
- the present invention provides a use of a composition comprising insulin and porous spherical calcium carbonate as a carrier for preparing a preparation for nasal absorption of insulin.
- FIG. 1 is a micrograph of porous spherical calcium carbonate that can be used as a carrier of the preparation of the present invention
- Figure 2 shows the serum insulin levels after intranasal administration of each preparation in the cynomolgus monkey. A graph showing the transition;
- Figure 3 is a graph showing the change in serum glucose concentration after intranasal administration of each preparation in cynomolgus monkeys;
- FIG. 4 is a graph showing the change in serum insulin concentration after administration of each preparation in a cynomolgus monkey.
- FIG. 5 is a graph showing the change in serum glucose concentration after administration of each preparation in a cynomolgus monkey.
- the “insulin” referred to in the present invention is not limited to its origin as long as it can be used for the treatment of diabetes in humans, and includes any modified or modified insulin. Therefore, the “insulin” referred to in the present invention can be obtained using human insulin, porcine purified insulin, semi-synthetic human insulin, human isoinsulin, etc. which are currently used clinically, and genetic engineering techniques. All human insulins and variants thereof having the same activity as human insulin can be mentioned.
- the calcium carbonate used as a carrier is at least in the form of porous spheres or at least occupied by cubic or trigonal crystals with a particle size of substantially 20 to 32 ⁇ m. Things.
- porous spherical can be understood from FIG. 1 showing a micrograph of an example of porous spherical calcium carbonate, but is a columnar or acicular crystallite or an aggregate of parallel intergrowths thereof. As a whole, it means a substantially spherical form.
- a parallel intergrowth is a growth state in which two or more crystal solids have evolved together with a certain crystal axis being parallel, and these or a large number of crystallites are integrated into one. By forming two spherical particles, the particles are assumed to be porous.
- Such porous spherical calcium carbonate has a particle size substantially in the range of 18 to 115 m.
- the term “substantially” means a range in which all (100%) of ideal particles or particles can exhibit the same characteristics or behaviors of the problem. For example, when using the word “substantially” for particle size, This means that at least 70%, preferably at least 90%, of the associated particles fall within the indicated particle size range.
- the preferred particle size of the porous spherical carbonated calcium is substantially in the range of 20 to 32 ⁇ m, more preferably 100% of the related particles has a particle size of 20 to 32 ⁇ m. ⁇ M. Further, those having a particle diameter within the above range and a median diameter of 22 jam or more and less than 30 m are particularly preferable.
- the calcium carbonate having the above preferred particle size is not the above-mentioned porous spherical one, but is mainly composed of, for example, a cubic or trigonal crystal which can be obtained by classification from a local product. Even though they have a particle size of 40 to 45 ⁇ m or more, they can function as a significantly better carrier for insulin than calcium carbonate having the same crystal habit.
- the porous spherical calcium carbonate that can be used in the present invention can be produced by a chemical synthesis method known per se and classified as required to obtain a desired particle size range.
- light calcium carbonate means a chemically synthesized product other than those produced naturally.
- such a synthetic calcium carbonate can be produced by calcining limestone and recarbonating it by a gas-liquid reaction.
- an additive capable of accelerating or adjusting the reaction may be present as necessary, and the desired synthetic calcium carbonate can be obtained by controlling the reaction temperature, stirring conditions, and the like.
- the calcium carbonate according to the present invention may contain, for example, magnesium and aluminum metal on the premise that the properties required for a local product are satisfied. Good.
- Table 1 below shows an example of the particle size distribution of the porous spherical calcium carbonate usable in the present invention and those having a specific particle size that can be classified and obtained.
- the calcium carbonate that can be used in the present invention has a specific surface area (BET method) of 1.5 m 2 Zg or more, and the specific surface area of commercially available light calcium carbonate is 0.1 to 0.3 m 2. It is characterized by having a significantly larger specific surface area than that of / g.
- Such calcium carbonate as a carrier or its fraction obtained through a suitable sieve can be combined with any amount of insulin as long as the insulin can be adsorbed or carried thereon as a monolayer or multilayer, Generally, 0.1 to 50% by weight, preferably 1 to 10% by weight, of insulin based on the total weight of the composition comprising both can be incorporated.
- the composition can be prepared by intimately kneading insulin and calcium carbonate with an appropriate amount of water using a kneading apparatus commonly used in the art, and freeze-drying the mixture.
- Such a composition may itself be a preparation for nasal absorption of insulin according to the present invention, but may adversely affect the preparation of the present invention during or after the preparation of the composition.
- Transmucosal absorption enhancers, stabilizers, protective agents, etc. may be added to the extent that they are not present.
- the preparation of the present invention is conveniently stored as it is or in a sealed package in a capsule.
- the nasal preparation of the present invention thus provided has significantly improved pharmacokinetic properties (eg, maximum blood concentration, area under the blood concentration curve, bioavailability) after nasal administration. .
- nasal administration devices known per se for example, nasal spray and the like can be used.
- the dose cannot be limited because the optimal dose varies depending on the disease state, age, body weight, etc. of the patient. However, referring to the pharmacokinetic parameters for cynomolgus monkeys described later, It is desirable to be determined.
- the preparation for nasal absorption of the present invention obtained as described above is superior to the novolin [N0Vo1in (TM)] subcutaneous administration of human insulin (genetical recombination) by Novo Nordisk. No toxicity was shown.
- the insulin used in this example was obtained from Novo Nordisk. It is human insulin (genetical recombination).
- test compound 3 to 18 male cynomolgus monkeys (body weight 2 to 7 kg) in each group was performed, and the blood insulin concentration and serum glucose concentration over time were measured, respectively. It was measured.
- Insulin and glucose concentrations were measured by the EIA method (enzyme immunoassay) and the G1ckG-6-PDH method, respectively.
- the method of administration of the formulation was determined by filling each formulation into a capsule and administering the formulation intranasally using an intranasal administration device (Jitterizer-1; Uniciadiex Co., Ltd.).
- Porous spherical type calcium carbonate in the force two Kuizaru [particle size: 20 to 32 m (hereinafter, referred PSCaC0 3 20 ⁇ 32 ⁇ M)], cubic carbonated calcium from station Method products [particle size: 20 to 32 m (hereinafter, CAC0 3 20 to 32 will leave m)], cubic calcium carbonate from the station method products as compared [particle size: 10 to 180 um (hereinafter, C aC0 3 10 ⁇ : 180 that m) the] and No vo 1 in (trademark) R40 result of determining the pharmacokinetic parameters of serum insulin (mean soil standard error) (sc) See Table 2 below.
- FIGS. 2 and 3 show the changes over time in the serum insulin concentration and the darcos concentration of the preparation for nasal absorption described above, respectively.
- the porous spherical type carbonate Karushiu arm [particle size from 18 to 115 111 (hereinafter, PS C aC0 3 18 ⁇ 115 / im ), particle size 20 ⁇ 38 ⁇ M ( below, PSCaC0 3 20 ⁇ 38 ⁇ M), particle size 20 to 32 / m (hereinafter, PSCaC0 3 20 ⁇ 32j m), particle size 25 to 32 m (hereinafter, P SC aC0 3 25 ⁇ 32 m) ], as well as cubic carbonate calcium ⁇ beam from station Method products [particle size 20-32 m (hereinafter, CaC0 3 20 ⁇ 32 / zm), particle size.
- the intranasal insulin preparation according to the present invention can increase serum insulin concentration without unacceptable irritation, and is therefore useful for the treatment of diabetes requiring insulin administration. Therefore, it can be used in the pharmaceutical manufacturing industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002378001A CA2378001A1 (en) | 2000-05-02 | 2001-04-26 | Preparation for nasal absorption of insulin |
US10/019,396 US6911213B2 (en) | 2000-05-02 | 2001-04-26 | Pernasally absorbable insulin preparations |
KR1020017016070A KR20020023233A (ko) | 2000-05-02 | 2001-04-26 | 인슐린의 경비흡수용 제제 |
EP01925973A EP1279403A1 (en) | 2000-05-02 | 2001-04-26 | Pernasally absorbable insulin preparations |
HK03105361.7A HK1053062A1 (zh) | 2000-05-02 | 2003-07-24 | 胰島素的經鼻吸收用製劑 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000133289A JP2001316286A (ja) | 2000-05-02 | 2000-05-02 | インスリンの経鼻吸収用製剤 |
JP2000-133289 | 2000-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001082950A1 true WO2001082950A1 (fr) | 2001-11-08 |
Family
ID=18641812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003642 WO2001082950A1 (fr) | 2000-05-02 | 2001-04-26 | Preparations d'insuline pouvant etre absorbees par voie pernasale |
Country Status (8)
Country | Link |
---|---|
US (1) | US6911213B2 (ja) |
EP (1) | EP1279403A1 (ja) |
JP (1) | JP2001316286A (ja) |
KR (1) | KR20020023233A (ja) |
CN (1) | CN1372472A (ja) |
CA (1) | CA2378001A1 (ja) |
HK (1) | HK1053062A1 (ja) |
WO (1) | WO2001082950A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103099777A (zh) * | 2011-11-15 | 2013-05-15 | 上海高科生物工程有限公司 | 以多孔碳酸钙为载体的生物酶水凝胶剂及制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045418A1 (fr) * | 2001-11-26 | 2003-06-05 | Daiichi Suntory Pharma Co., Ltd. | Compositions médicales pour absorption nasale |
JPWO2004113332A1 (ja) * | 2003-06-19 | 2006-07-27 | 小野薬品工業株式会社 | 経鼻製剤 |
US7115561B2 (en) | 2004-09-22 | 2006-10-03 | Patterson James A | Medicament composition and method of administration |
CN106138011B (zh) * | 2016-08-05 | 2018-12-25 | 浙江理工大学 | 碳酸钙/透明质酸复合药物载体及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0681833A2 (en) * | 1994-05-11 | 1995-11-15 | Dott Research Laboratory | Nasally administrable compositions |
JPH11322582A (ja) * | 1998-05-06 | 1999-11-24 | Dot:Kk | 経鼻吸収用鼻粘膜付着・滞留型キャリヤ |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62223131A (ja) * | 1986-03-26 | 1987-10-01 | Nitto Electric Ind Co Ltd | 持続性鼻疾患治療剤 |
US5948438A (en) * | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
US6197328B1 (en) * | 1999-08-20 | 2001-03-06 | Dott Research Laboratory | Nasally administrable compositions |
-
2000
- 2000-05-02 JP JP2000133289A patent/JP2001316286A/ja active Pending
-
2001
- 2001-04-26 KR KR1020017016070A patent/KR20020023233A/ko not_active Application Discontinuation
- 2001-04-26 CA CA002378001A patent/CA2378001A1/en not_active Abandoned
- 2001-04-26 EP EP01925973A patent/EP1279403A1/en not_active Withdrawn
- 2001-04-26 CN CN01801146A patent/CN1372472A/zh active Pending
- 2001-04-26 WO PCT/JP2001/003642 patent/WO2001082950A1/ja not_active Application Discontinuation
- 2001-04-26 US US10/019,396 patent/US6911213B2/en not_active Expired - Fee Related
-
2003
- 2003-07-24 HK HK03105361.7A patent/HK1053062A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0681833A2 (en) * | 1994-05-11 | 1995-11-15 | Dott Research Laboratory | Nasally administrable compositions |
JPH11322582A (ja) * | 1998-05-06 | 1999-11-24 | Dot:Kk | 経鼻吸収用鼻粘膜付着・滞留型キャリヤ |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103099777A (zh) * | 2011-11-15 | 2013-05-15 | 上海高科生物工程有限公司 | 以多孔碳酸钙为载体的生物酶水凝胶剂及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20020023233A (ko) | 2002-03-28 |
EP1279403A1 (en) | 2003-01-29 |
CN1372472A (zh) | 2002-10-02 |
US6911213B2 (en) | 2005-06-28 |
CA2378001A1 (en) | 2001-11-08 |
HK1053062A1 (zh) | 2003-10-10 |
JP2001316286A (ja) | 2001-11-13 |
US20030082240A1 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030232748A1 (en) | Novel formulations | |
ES2739023T3 (es) | Aglomeración controlada | |
AU2003238862B9 (en) | Formulations for amylin agonist peptides | |
Khopade et al. | Development of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half-generation poly (amidoamine) dendrimer | |
PL194244B1 (pl) | Preparat insulinowy w postaci roztworu i jego stosowanie | |
US20130287852A1 (en) | Compositions for nasal administration of pharmaceuticals | |
US20060127480A1 (en) | Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof | |
TWI277425B (en) | Pulmonary administration of dry powder formulations for treating infertility | |
CN1481236A (zh) | 气凝胶粉末治疗剂 | |
Otsuka et al. | Efficacy of the injectable calcium phosphate ceramics suspensions containing magnesium, zinc and fluoride on the bone mineral deficiency in ovariectomized rats | |
CN110101846B (zh) | 一种低突释率的索玛鲁肽微球及其制备方法 | |
JP4721212B2 (ja) | インスリンの経鼻投与用組成物 | |
CN1438881A (zh) | 胰岛素控释制剂及其方法 | |
WO2001082950A1 (fr) | Preparations d'insuline pouvant etre absorbees par voie pernasale | |
US20210022994A1 (en) | Sustained release trepostinil-compound microparticle compositions | |
CN101422431A (zh) | 胰岛素经鼻给药制剂 | |
JP4212019B2 (ja) | 薬物の経鼻投与用組成物 | |
WO2004078211A1 (ja) | 粉末経鼻投与製剤 | |
US20050037081A1 (en) | Novel formulation | |
US20110207653A1 (en) | Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent | |
KR100342746B1 (ko) | 인슐린의 방출제어제제 및 그 방법 | |
WO2023285357A1 (en) | A glucose-sensitive insulin-loaded microparticle | |
JP2002128704A (ja) | 経鼻投与用組成物 | |
WO2021009027A1 (en) | High concentration insulin formulation | |
JP2002193830A (ja) | 経鼻投与用医薬製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 01801146.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017016070 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2378001 Country of ref document: CA Ref document number: 10019396 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001925973 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001925973 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001925973 Country of ref document: EP |